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Abstract: Honey has a long history in the treatment of wounds, where claims of its therapeutic 
properties include the inhibition of a wide range of infectious agents as well as an ability to 
promote rapid wound healing. However, honey is not a uniform product, and its chemical 
composition can be influenced by multiple factors. The availability of modern, licensed dress-
ings containing medical grade honey has garnered renewed interest in its clinical potential for 
conventional wound care. Laboratory investigations are beginning to explain at a cellular and 
molecular level the effects of specific honeys on certain microorganisms, but the clinical evidence 
of its antimicrobial effects is limited at present. The aim of this review is to demonstrate the 
chemical complexity of honey, to describe the mechanisms of antibacterial action reported to 
date, and to collate the evidence that provides insight into antimicrobial claims for honey.
Keywords: medical grade honey, wound infection, antibacterial activity, antibiofilm activity, 
wound healing
Introduction
The last 10 years has seen an ancient wound remedy, honey, integrated into modern 
medicine in developed countries. Historically, honey has long been regarded as 
a prized substance, with exceptional properties.1 Texts and artifacts indicate that 
honey has been used therapeutically for thousands of years but that ancient users 
exercised discrimination in selecting honeys for various medicinal conditions and 
employed different honeys for different diseases.2 Now, a narrow range of honeys 
are being used in licensed devices designed for wound care in Australasia, Europe, 
and North America.
Although many laboratory studies demonstrating the inhibition of microorganisms 
by honey were published before the start of this century, relatively few utilized either 
fully characterized honey or named proprietary products. Hence, their relevance to 
wound care is limited, and only more recent studies are discussed in depth here. One 
important issue in evaluating laboratory and clinical evidence of the antibacterial 
efficacy of honey is to understand that not all honeys are alike. Blossom honeys are 
derived from the nectar that is collected by bees from the flowers of plants, shrubs, 
and trees, and they are distinct from honeydew honeys, which are produced by bees 
that collect secretions from injured plants, shrubs, and trees. Not only does the floral 
source influence honey composition, but also the species of bee, geographical loca-
tion, harvesting process, subsequent storage conditions, and time impact on chemical 
characteristics.3–5 Thus generalizations about honey are not always possible, and only 
bees foraging known plants contained within a greenhouse will naturally produce 
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honey of a predictable and consistent quality. Otherwise, 
sophisticated chemical analysis and blending of particular 
honeys can produce a reproducible honey sample. Because 
contamination of honey by antibiotics, pesticides, or micro-
organisms has been reported,6 honeys destined for medical 
use should ideally be produced hygienically in unpolluted 
areas. Unlike honeys produced for human ingestion, those 
selected for use in medical devices are usually chosen on 
the basis of their antibacterial potency. Several medical 
grade honeys are being used clinically in licensed wound 
care products (Table 1).
Chemical composition of honey
A detailed analysis of the chemical composition of blossom 
honey produced by European honeybees (Apis mellifera) was 
derived from a study of 490 American blossom honeys con-
ducted at Cornell University.7 Essentially, honey is a super-
saturated solution comprising approximately 80% sugars by 
weight, predominantly fructose and glucose, with sucrose, 
maltose, and many other sugars at much lower concentrations. 
The low level of water (less than 20%) is generally not avail-
able to microorganisms, as these molecules are tightly bound 
to sugars. Acidity in honey is due to a wide range of organic 
acids, with gluconic acid most common; pH values between 
3.4 and 6.1 have been reported. Low concentrations of pro-
teins, vitamins, minerals, and trace elements are common 
in honeys. Many studies have demonstrated the complexity 
of honey chemistry; characterization on the basis of pollen 
content,8 phenolic components,9 flavonoids,10 or antioxi-
dants11 is possible, but a combination of several approaches 
may be needed. Even samples of honey from the same floral 
source (manuka) were recently divided into three groups by 
chemical analysis.12
Antimicrobial activity of honey
The inherent chemical composition of honey (high sugar con-
tent, low water content, and acidity) prevents the growth of 
vegetative microbial cells within honey, but microbial spores 
persist.13 A myriad of additional factors contribute to the anti-
microbial properties of honey. The first antibacterial factor 
discovered in honey was hydrogen peroxide (initially known 
as inhibine), which is not detectable in undiluted honeys. 
However, most honeys generate hydrogen peroxide on dilu-
tion by the activation of glucose oxidase (an enzyme secreted 
into honey by worker bees).14 This enzyme oxidizes glucose 
to gluconic acid with the release of hydrogen peroxide. Low 
concentrations of hydrogen peroxide are normally generated 
over 24 hours, with maximal yields obtained from honey 
diluted to concentrations between 50% and 30%.15 It has 
been suggested that significant levels of antibacterial activity 
might be generated from honey dressings in heavily exuding 
wounds.15 The levels of hydrogen peroxide generated by 
honeys are influenced by the floral source, processing, and 
storage,4,5 but exposing honey to elevated temperatures will 
denature glucose oxidase. Hence many honeys destined for 
human consumption, especially those runny honeys that have 
been processed to delay the onset of crystallization, usually 
have low levels of antibacterial potency. Honeys that read-
ily produce hydrogen peroxide when diluted are known as 
peroxide honeys to distinguish them from those that do not, 
which are known as nonperoxide honeys.3
Another important antibacterial component present in 
some honeys, particularly manuka honey, is methylglyoxal 
(MGO).16,17 It is also present in many foods; levels in honey 
vary, even within different samples of manuka honey.18–21 
MGO has been shown to form from dihydroxyacetone, which 
is characteristically present in the nectar of manuka flowers.19 
Recently, it was found that adding MGO to manuka honey 
reduced the generation of hydrogen peroxide,22 and this may 
explain why some researchers have failed to detect hydrogen 
peroxide generation in manuka honey.3,20
A glycoside named leptosin has recently been discovered 
in manuka honey, together with methyl syringate.23 Leptosin 
is thought to contribute to the antibacterial characteristics of 
manuka honey.23
One additional antibacterial component called bee 
defensin-1 was discovered in Revamil® (Bfactory Health 
Products, Rhenen, the Netherlands) source (RS) honey after 
the inhibitory effects of hydrogen peroxide and MGO had 
been enzymatically neutralized.20 Bee defensin-1 is an anti-
microbial peptide with marked activity against Gram-positive 
bacteria that is part of the insect’s immune response. It was not 
detected in a sample of manuka honey,22 but recently MGO 
has also been shown to modify proteins in manuka honey and 
to abrogate the antibacterial activity of bee defensin-1.24
Table 1 examples of medical grade honeys used in modern 
wound care products
Type of  
honey
Country  
of origin
Botanical  
source
Bee 
species
Chestnut Slovenia Castanea sativa Apis mellifera
Manuka New Zealand Leptospermum 
scoparium
Apis mellifera
Thyme France Thymus vulgaris Apis mellifera
Revamil®  
source honey
The Netherlands Unspecified Apis mellifera
Multifloral Chile Mixed Apis mellifera
Note: Revamil® manufactured by Bfactory Health Products, Rhenen, the Netherlands.
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Interactions between proteins and sugars by the Maillard 
reaction cause non-enzymatic browning in honeys and other 
foods and lead to the formation of a range of complex prod-
ucts with antioxidant and antibacterial activity.25 Melanoidins 
arise in this way and have been found to develop in several 
Canadian honeys with either time or heating.26
Thus, the antibacterial activity of honey comprises 
multiple factors that depend on diverse influences, and the 
therapeutic potential of a honey sample cannot be assumed 
by simply identifying its botanical origin. Medical grade 
honeys are currently selected on the basis of their antibac-
terial activity, but more sophisticated characterization of 
anti-inflammatory and antioxidant activity may become 
important in the future.
Mechanisms for the inhibition  
of bacteria attributed to honey
A wide range of microbial species have been shown to be 
susceptible to honey in laboratory tests using suspensions 
of planktonic organisms,27 but only those of relevance to 
wound infections, particularly antibiotic-resistant strains, 
will be included here. Several studies have demonstrated the 
susceptibility of antibiotic-resistant and multidrug-resistant 
strains to honey.28–36 Thus, honey clearly exhibits broad 
spectrum antimicrobial activity.
Unlike an antibiotic which normally targets a specific 
site within an infective agent, the inhibitory effects of a 
honey varies according to the species treated, and multiple 
effects are often observed. At present, most published data 
concerns the inhibitory effects of manuka honey. Exposure 
of Staphylococcus aureus and methicillin-resistant S. aureus 
(MRSA) to manuka honey caused the accumulation of cells 
with fully formed cross walls that failed to complete the cell 
division cycle.37,38 Loss of activity of autolysin (an enzyme 
involved in cleavage of bacterial cell wall components) 
explained how cell division in these Gram-positive bacteria 
had been prevented.38 Yet, manuka honey caused structural 
changes in the cell wall of Pseudomonas aeruginosa that 
caused cell lysis and death.39 Further examination by fluo-
rescent microscopy and atomic force microscopy revealed 
extensive changes in the cell surface, and the loss of structural 
integrity was found to be related to the downregulation of a 
protein usually involved in cell envelope stability.40 Hence, 
exposure of this Gram-negative bacterium to manuka honey 
resulted in cellular effects that were markedly different to 
those observed in MRSA.
Comparing the proteins present in bacteria exposed 
to honey with those in untreated bacteria has allowed the 
characterization of multiple intracellular effects. With 
manuka honey, a unique mode of inhibitory action against 
S. aureus was deduced.41 Following treatment of MRSA with 
manuka honey, analysis of proteins showed how downregu-
lation of a stress protein limited the bacterium’s ability to 
survive honey-stressed conditions.42
This approach has been employed in bacteria with regard 
to monitoring alterations in gene expression; insight into 
the complex and unusual antibacterial activity of manuka 
honey against Escherichia coli was obtained from analysis 
of gene transcription following honey treatment.33 Similarly, 
investigating changes in both protein and gene expression 
in honey-treated MRSA revealed the downregulation of a 
global regulator, with widespread knock-on effects on the 
expression of genes controlling virulence, cell to cell com-
munication, and biofilm formation.43 These effects have not 
yet been demonstrated in bacteria in wounds treated with 
honey, but if virulence were to be reduced in vivo, and biofilm 
formation prevented, then the incidence of both acute and 
chronic infections in wounds might be decreased. Until those 
investigations are completed, one can only speculate on the 
clinical implications of these laboratory observations.
Although MGO in manuka honey has been suggested as 
the principal antibacterial component,16,17 it is not exclusively 
responsible for the antibacterial effects described above;38 it is 
likely that other bioactive components may yet be found.
In fact, with the information now available to illustrate 
the complicated chemistry of honey, it is not surprising that 
the mechanisms by which different kinds of honey inhibit 
different microbial species vary. This was clearly illustrated 
by the distinct bactericidal effects displayed by manuka honey 
and RS honey against four bacteria.21 Whereas manuka honey 
killed only Bacillus subtilis rapidly, RS killed B. subtilis, 
E. coli, and P. aeruginosa rapidly, but both killed all bacteria 
tested (including MRSA) after 24 hours. Similarly, differing 
effects on the growth, cellular morphology, and appearance 
of DNA were observed in four species of bacteria (B. subtilis, 
E. coli, S. aureus, and P. aeruginosa) following incubation 
with Australian honeys of three different floral origins that 
had been carefully characterized in geographical and chemi-
cal terms.44
Honeys that generate hydrogen peroxide were shown to 
cause oxidative damage that restricted bacterial growth and 
caused cytotoxic degradation of DNA due to the formation 
of hydroxyl radicals.45,46 These effects have been reported 
for E. coli, B. subtilis, MRSA, and vancomycin-resistant 
enterococci and appear to involve some components in honey 
that have not yet been identified.
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Antibiofilm activity  
of manuka honey
Following the discovery of an association between wound 
chronicity and biofilms,47 the search for effective antibiofilm 
agents has intensified. Tolerance of biofilms to antibiotics48 
calls for novel antimicrobial strategies, and two approaches to 
controlling biofilms in wounds have emerged. One involves 
preventing the formation of a biofilm, which can be achieved 
by either interfering with adherence to host cells and tissues, 
or by preventing biofilm maturation through interfering with 
cellular communication, known as quorum sensing (QS). The 
other approach is to disrupt an established biofilm. Evidence 
to show that honey displays activity in each of these lines of 
attack is accumulating.
The dominant sugar in honey, fructose, was found to inter-
fere with the binding of P. aeruginosa to erythrocytes in vitro, 
by binding to the bacterial lectins and thereby blocking their 
binding to erythrocyte receptors.49  Interference in bacteria 
adherence has also been investigated in Streptococcus pyo-
genes, and manuka honey prevented biofilm formation of S. 
pyogenes in vitro by decreasing the expression of two important 
surface proteins that act as adhesins in facilitating bacterial 
binding to fibronectin.50 Without attachment, microbial species 
can neither initiate infection nor initiate biofilm formation.
The ability of 29 honeys to interfere with QS was explored 
in a Spanish study using a pigmented bacterial reporter assay. 
Four honeys had notable activity, and chestnut honey was 
found to be the most effective QS inhibitor. Chemical analysis 
showed that the phenolic components in the honey samples 
were not responsible for this effect.51 Manuka honey caused 
inhibition of QS in P. aeruginosa.52 Using low concentrations 
of manuka honey, sugars were implicated in this effect, and 
it was revealed that the impact of disrupting QS repressed 
associated networks of virulence genes. Thus, P. aeruginosa 
was inhibited at high concentrations of manuka honey, and 
virulence was decreased at low concentrations.52 QS inhibi-
tion by manuka honey in MRSA and repressed virulence has 
already been described above.43 Although E. coli O157:H7 
is not a wound pathogen, it is worth noting here that low 
concentrations of honey have been shown to reduce QS, 
virulence, and biofilm formation.53 Another example of the 
effect of low concentrations of manuka honey on virulence 
was reported in P. aeruginosa, where siderophore production 
was inhibited.54 In bacteria, siderophores are also regulated by 
QS; they facilitate the acquisition of iron from host resources 
in order to promote bacterial growth.
Several studies have investigated the ability of honey 
to disrupt established biofilms in laboratory models; all 
indicate that higher concentrations are required to disrupt 
established biofilms than those required to prevent biofilm 
formation.50,55–60 MGO, the active component of manuka 
honey, inhibited biofilms of each of P. aeruginosa and 
MRSA,61 but disruption of S. aureus biofilms by MGO alone 
required higher concentrations than the levels of MGO in 
manuka honey, which gave equivalent inhibitory effects. 
Hence MGO contributes to the antibiofilm activity of manuka 
honey but is not exclusively responsible for it.62 A similar 
deduction for manuka honey was made recently with a range 
of S. aureus strains with varying abilities to form biofilms.63 
Importantly, in this study manuka honey was able to penetrate 
the biofilm to kill embedded bacteria in some instances.
Many of the biofilm inhibition studies published to date 
have relied on estimating biofilm biomass or metabolic 
activity following exposure to honey, but four studies have 
also provided visual evidence of biofilm disruption obtained 
by fluorescent, electron microscopy, and/or atomic force 
microscopy.60,63–65 Hence, the ability of honey to prevent and 
to disrupt established biofilms has been demonstrated in vitro, 
but these effects have yet to be tested in vivo.
The efficacy of honey in clinical use
A large quantity of clinical evidence exists for the use of honey 
in wound care. Randomized clinical trials dating from 1991 
involve a wide range of wounds, from acute wounds such as 
burns and surgical incision sites to chronic wounds such as leg 
ulcers, pressure ulcers, diabetic foot ulcers, and malignant 
wounds. Studies have been conducted in countries as far apart 
as Norway and South Africa, and New Zealand and the UK. 
The variety of honeys includes those of unspecified floral origin 
from Egypt, India, Iran, Malawi, Malaysia, Pakistan, and Yemen 
as well as Aloe vera and Jamun, Jarrah, and Jambhul honeys. 
Manuka honey is a relatively recent innovation. The systematic 
reviews completed to date have generally used wound healing 
as an endpoint rather than antibacterial activity.66–70 Inconsistent 
study methodologies mean that meta-analysis of the clinical 
evidence is not possible.67,70 Most reviews indicate that the 
quality of the clinical evidence for the efficacy of honey in 
promoting wound healing is low66–70 although there is some 
evidence to support the use of honey in burns.70,71 In many 
clinical trials where honey was compared to another topical 
agent, statistically significant differences were rarely found. 
Clearly, better designed studies are essential, but that is also 
true for many other topical antimicrobial agents conventionally 
used on wounds. For the future, multicenter trials with larger 
patient cohorts, improved methodologies, and a range of clinical 
outcomes wider than wound closure alone are indicated.
 
Ch
ro
ni
c 
W
ou
nd
 C
ar
e 
M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
5.
19
4.
13
2.
15
1 
on
 0
3-
Fe
b-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Chronic Wound Care Management and Research 2014:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
19
Honey as an effective antimicrobial treatment for chronic wounds
One limitation of the published systematic reviews is that 
none have delineated between clinical trials with licensed 
wound care products and those with either unconventional 
comparators (such as boiled potato skins) or locally produced, 
uncharacterized honeys. With the advent of quality assured, 
modern, licensed wound care products that are produced with 
medical grade honey under the defined conditions of good 
manufacturing practices, it is difficult to justify the com-
parison of clinical data derived from such products with data 
obtained using honeys from less well-characterized sources, 
particularly now that it is known that chemical changes occur 
in honey with time. Proprietary products have expiry dates, 
whereas the age of locally sourced honeys may not be known. 
Furthermore, licensed wound care products containing honey 
are usually sterilized by gamma irradiation, whereas unreg-
istered ones are not. Gamma irradiation of honey has been 
shown to not affect antibacterial activity72,73 although it may 
increase antioxidant activity.74,75 Clinical practice ought to be 
informed by pertinent clinical evidence. Since all practitioners 
do not have access to the diverse range of licensed wound care 
products containing medical grade honey, it might be help-
ful to separately review those clinical studies where medical 
grade honey was utilized from those without, or else conduct 
a sensitivity analysis with and without them.
The increasing breadth of knowledge concerning the influ-
ence of honey on the wound healing process was recently dem-
onstrated in one review where explanations of the rationale for 
each therapeutic claim for honey (such as debriding action, 
anti-inflammatory action, antioxidant activity, and increased 
healing) were included.76 A review of the immunomodulatory 
role of honey in wound healing was recently published.77
Antibacterial activity  
of honey in vivo
Evidence of the eradication of bacteria from skin and wounds 
is conflicting. Microbial colonization on the skin of the fore-
arms of healthy volunteers was diminished by 100-fold in 48 
hours following topical application of Revamil® medical grade 
honey compared to untreated volunteers.32 Yet, in critically ill 
patients, the same honey did not reduce skin colonization at 
the insertion sites of central venous catheters when applied 
in addition to skin disinfection with 0.5% chlorhexidine in 
70% alcohol as compared to the control group treated with 
standard care alone.78 Likewise, in a randomized control trial 
in patients receiving hemodialysis via tunneled, cuffed central 
venous catheters, Medihoney™ (Medihoney Pty Ltd, Brisbane, 
Australia [at time of study, but now available from Derma 
Sciences Inc, Toronto, Canada]) did not significantly reduce 
bacteremia compared to mupirocin. However, the advantage 
of using honey to minimize the risks of selecting mupirocin-
resistant strains led to a change in clinical practice in favor 
of honey.79 Yet, a subsequent multicenter study to determine 
whether daily application of Medihoney™ at the catheter 
exit site would increase the time to peritoneal dialysis-related 
infection compared with standard exit site care, plus intranasal 
mupirocin in nasal carriers of S. aureus, showed no significant 
difference, and the authors concluded that honey could not be 
recommended routinely to prevent infection.80
In malignant wounds, a randomized trial to compare the 
effect on qualitative bacteriology of a honey dressing to a 
silver dressing found no significant differences in either the 
flora recovered or the wound size.81
Evidence for the potential of manuka honey to control 
MRSA in wounds has been reported. Initially, only case 
reports of MRSA eradication were available,82–84 but success-
ful healing in cohorts of patients with maxillofacial wounds85 
or pediatric oncology wounds indicated effective control of 
MRSA.86 In one randomized control trial of venous leg ulcers, 
eradication of MRSA by manuka honey in 70% of chronic 
venous leg ulcers was reported.87 Later, a feasibility study 
to evaluate the ability of honey to reduce the incidence of 
wound infection showed a significant reduction in hospital 
stay compared to the control group (conventional dressings 
used) but concluded that larger studies were needed.88
An ex vivo human burns model has been used to compare 
the bactericidal and cytotoxic effects of a honey-based gel 
with silver sulfadiazine against P. aeruginosa. Honey was less 
effective at reducing bacterial load than silver sulfadiazine 
but gave rise to better reepithelialization. The authors sug-
gested that honey be applied at higher frequency.89 Similarly, 
an ex vivo porcine skin model has been used to evaluate the 
efficacy of five topical antimicrobial agents and four moisture 
dressings against 3 day mature biofilms of P. aeruginosa. Log 
reductions between 5 and 7 were reported for time-release 
silver gel and cadexomer iodine dressings, and 2.3 for a 
calcium alginate Leptospermum honey dressing.90
Conclusion
Although the clinical evidence for the antibacterial activity 
of honey is restricted, laboratory studies explain how suspen-
sions of some antibiotic-resistant bacteria are inhibited and 
that honey possesses antibiofilm activity. There are no reports 
of cytotoxicity for honey, and another clinical advantage 
is that resistance to honey has not yet been identified in 
microorganisms isolated directly from patients. Training 
experiments in which prolonged exposure of planktonic 
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bacteria to antibiotics leads to the emergence of antibiotic-
resistant strains33 did not cause the emergence of honey-
resistant strains following long-term exposure to manuka 
honey.33,91 However reduced susceptibility to antibiotics and 
manuka honey has recently been detected in persister cells 
derived from treated biofilms. These were probably small 
colony variants which are often unstable and prone to back-
mutation, so further genetic characterization is required.92
Honey, like other topical antimicrobial agents, seems to have 
a place in modern wound care. It is not a panacea; some patients 
complain of mild, transient stinging sensations, yet others find 
it soothing. The complexity of the various factors that influence 
the chemistry of honey and the ways in which different honeys 
inhibit microbial species is beginning to be understood. These 
factors have not yet been fully integrated into the evaluation 
of clinical data, and no clinical comparisons between different 
honeys have been attempted. Honey is a complex natural sub-
stance, and it is probable that additional bioactive components 
will be isolated and identified in the future.
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